Franklin Street Advisors’s Pacira BioSciences PCRX Stock Holding History

Franklin Street Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-12,325	Closed	-$653K	–	213
2016 Q1	$653K	Buy	12,325 +6,125	+99%	+$358K	0.13%	123
2015 Q4	$476K	Buy	+6,200	New	+$351K	0.09%	146
2015 Q3	–	Sell	-4,050	Closed	-$287K	–	234
2015 Q2	$287K	Sell	4,050 -900	-18%	-$70.9K	0.05%	187
2015 Q1	$439K	Sell	4,950 -675	-12%	-$68.5K	0.08%	144
2014 Q4	$499K	Sell	5,625 -2,150	-28%	-$203K	0.1%	134
2014 Q3	$754K	Hold	7,775	–	–	0.14%	135
2014 Q2	$714K	Sell	7,775 -2,925	-27%	-$223K	0.14%	146
2014 Q1	$749K	Sell	10,700 -4,425	-29%	-$301K	0.15%	142
2013 Q4	$870K	Sell	15,125 -6,525	-30%	-$343K	0.18%	124
2013 Q3	$1.04M	Sell	21,650 -8,450	-28%	-$308K	0.23%	103
2013 Q2	$873K	Buy	+30,100	New	+$871K	0.21%	126

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Street Advisors's PCRX Position: Q2 2016 in Review

Franklin Street Advisors sold out of Pacira BioSciences (PCRX) in Q2 2016, closing a stake of 12,325 shares — an estimated $653K sold.

Franklin Street Advisors first reported a position in PCRX in Q2 2013 and held it in 11 quarters. The position peaked at $1.04M in Q3 2013. 183 funds tracked by Wall St. Rank hold PCRX as of Q2 2016.

Franklin Street Advisors reported no remaining Pacira BioSciences position as of Q2 2016 after selling out during the quarter.
Franklin Street Advisors sold 12,325 Pacira BioSciences shares in Q2 2016, an estimated $653K.
Franklin Street Advisors first reported a position in Pacira BioSciences in Q2 2013 and held it in 11 quarters.
Franklin Street Advisors's Pacira BioSciences position peaked at $1.04M in Q3 2013.
183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2016.

Based on Franklin Street Advisors's 13F filing for Q2 2016, filed 11 Jul 2016.